{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-221861","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2022-08-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.098833+00:00","generated_at":"2026-06-23T23:21:42.868532+00:00","sec_items":["8.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Halozyme upsizes and prices $625M convertible notes due 2028, conversion premium ~30%","bullets":["$625M aggregate principal; initial purchasers have option for additional $95M.","1.00% annual interest rate; conversion price ~$56.02/share, 30% above $43.09 close.","Use of proceeds: ~$77.6M to exchange existing 2024 notes, up to $200M for share repurchases, $250M term loan repayment.","Entered capped call transactions with initial cap price ~$75.41/share to reduce dilution.","Expects to close offering on August 18, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-221861","json":"https://secwatch.observer/filing/0001193125-22-221861.json","markdown":"https://secwatch.observer/filing/0001193125-22-221861.md","text":"https://secwatch.observer/filing/0001193125-22-221861.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000119312522221861/0001193125-22-221861-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000119312522221861/d335715d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T23:21:42.868532+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}